Close

Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

Go back to Wells Fargo Downgrades Myriad Genetics (MYGN) to Market Perform

Myriad Genetics Reports Fiscal Fourth-Quarter 2016 Financial Results

August 9, 2016 4:06 PM EDT

Total Revenues of $186.5 MillionAdjusted EPS of $0.36 and Diluted EPS of $0.32Company Issues Fiscal First-Quarter 2017 and Fiscal Year 2017 Financial Guidance  

SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal fourth-quarter 2016, provided an update on recent business highlights and provided fiscal first-quarter 2017 and fiscal year 2017 financial guidance. 

"Fourth-quarter performance met our expectations, and we continue to make substantial progress on advancing our product portfolio and growing Myriad into a... More